Previous 10 | Next 10 |
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the AACR Virtual Annual Meeting II, taking place June...
Alpine Immune Sciences ( ALPN +5.4% ) presents updated results from its phase 1 study of ALPN-101, dual CD28/ICOS costimulation antagonist for autoimmune and inflammatory diseases. More news on: Alpine Immune Sciences, Inc., Healthcare stocks news, Read more ...
-- ALPN-101 was well tolerated and exhibited potent pharmacodynamic activity, enabling Phase 2 development -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory dise...
First presentation of Alpine’s Variant Tumor Necrosis Factor (TNF) Receptor Domain (vTD) Program demonstrating expanded applicability of its directed evolution platform Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developin...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that the company will present two posters at the EULAR 2020 E-Congress, taking place virtu...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced its participation in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare...
Alpine Immune Sciences (NASDAQ: ALPN ): Q1 GAAP EPS of -$0.30 beats by $0.17 . More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Granted FDA Orphan Drug Designations for ALPN-101 in Acute GVHD - - BALANCE and NEON-1 Trials Open for Enrollment - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/in...
- NEON-1 is now open for enrollment for patients with advanced malignancies - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today presented the des...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
News, Short Squeeze, Breakout and More Instantly...
Alpine Immune Sciences Inc. Company Name:
ALPN Stock Symbol:
NASDAQ Market:
Alpine Immune Sciences Inc. Website:
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades...
2024-05-19 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceutic...